Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyun Min | - |
dc.contributor.author | Lim, Jung Soo | - |
dc.contributor.author | Lee, Byung-Wan | - |
dc.contributor.author | Kang, Eun-Seok | - |
dc.contributor.author | Lee, Hyun Chul | - |
dc.contributor.author | Cha, Bong-Soo | - |
dc.date.available | 2019-03-08T17:42:19Z | - |
dc.date.issued | 2015-03 | - |
dc.identifier.issn | 2093-596X | - |
dc.identifier.issn | 2093-5978 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9780 | - |
dc.description.abstract | Background: Sitagliptin is a novel antidiabetic agent with a low risk for hypoglycemia. We investigated the efficacy and safety of sitagliptin when patients switched from a sulfonylurea to sitagliptin and identified good candidates for the switch. Methods: Sixty-one patients with type 2 diabetes switched from glimepiride with metformin to sitagliptin with metformin due to clinical hypoglycemia. Serum glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and 2-hour postprandial plasma glucose (2h-PPG) before and 12 and 24 weeks after the drug switch were checked. Results: HbA1c and FPG levels did not change 12 or 24 weeks after the switch; however, the 2h-PPG level decreased from 218.0 +/- 67.5 mg/dL at baseline to 197.1 +/- 69.9 mg/dL at 12 weeks and 192.3 +/- 67.4 mg/dL at 24 weeks after switching drugs (P=0.045, P=0.018, respectively). All but one patient no longer experienced hypoglycemia after discontinuing glimepiride. In a multivariate logistic regression analysis, a high homeostasis model assessment of insulin resistance and low baseline HbA1c level were independent predictors of an HbA1c <= 7% after switching to sitagliptin. Conclusion: Glycemic control was not aggravated in patients 24 weeks after the drug switch, and symptomatic hypoglycemia decreased significantly. Patients with dominant insulin resistance may be good candidates for switching from a sulfonylurea to sitagliptin to reduce hypoglycemia. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN ENDOCRINE SOC | - |
dc.title | Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus | - |
dc.type | Article | - |
dc.identifier.doi | 10.3803/EnM.2015.30.1.84 | - |
dc.identifier.bibliographicCitation | ENDOCRINOLOGY AND METABOLISM-ENM, v.30, no.1, pp 84 - 91 | - |
dc.identifier.kciid | ART001977905 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000409632300013 | - |
dc.identifier.scopusid | 2-s2.0-84955440494 | - |
dc.citation.endPage | 91 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 84 | - |
dc.citation.title | ENDOCRINOLOGY AND METABOLISM-ENM | - |
dc.citation.volume | 30 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | DPP-4 inhibitors | - |
dc.subject.keywordAuthor | Hypoglycemia | - |
dc.subject.keywordAuthor | Diabetes mellitus | - |
dc.subject.keywordAuthor | type 2 | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.